PBLS logo

PARABILIS MEDICINES INC

PBLSNASDAQ
πŸ† #1490 by market capUS Equity
$31.91β–Ό $0.65 (βˆ’2.03%)
πŸŒ… Pre-market$31.91β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track PBLS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.0%
7dβ–Ό 4.3%
14dβ–Ό 13.7%
30dβ–Ό 18.2%
ytdβ€”
1yβ€”
🏦Market Cap
$3.72B
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
76
Good

Trading Snapshot

Day Range
$31.69 – $32.27
52-Week Range
$24.51 – $42.49
Volume
$2.53B
Avg Volume
$2.21B
Shares Outstanding
116.6M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$590M
Last Q Revenue
$148,000
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-2.04
Dividend Yield
β€”

Why Investors Own PBLS

  • βœ“High-growth profile β€” revenue up +17.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 62% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PBLS logo

PARABILIS MEDICINES INC

PBLS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$152Mβ–² +20.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$124Mβ–² +18.7% YoY
StockOtter Β· stockotter.space

About PARABILIS MEDICINES INC

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy5
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Seeking AlphaΒ·13d ago

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

GlobeNewsWireΒ·29d ago

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlo

GlobeNewsWireΒ·Aug 25

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unloc

Seeking AlphaΒ·Aug 14

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support cl

GlobeNewsWireΒ·Aug 13

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Advanced zolucatetide across multiple Wnt/Ξ²-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors

247 WallstΒ·Jul 6

Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter ea